CY1105179T1 - Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων - Google Patents

Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων

Info

Publication number
CY1105179T1
CY1105179T1 CY20061101216T CY061101216T CY1105179T1 CY 1105179 T1 CY1105179 T1 CY 1105179T1 CY 20061101216 T CY20061101216 T CY 20061101216T CY 061101216 T CY061101216 T CY 061101216T CY 1105179 T1 CY1105179 T1 CY 1105179T1
Authority
CY
Cyprus
Prior art keywords
drugs
malignant tumors
immune treatment
tumors
immune
Prior art date
Application number
CY20061101216T
Other languages
English (en)
Inventor
Claudia Ulbrich
Klaus-Dieter ROCKENSÜSS
Armin Grossmann
Original Assignee
Liponova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liponova Ag filed Critical Liponova Ag
Publication of CY1105179T1 publication Critical patent/CY1105179T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Περιεχόμενο της παρούσας εφεύρεσης είναι μια σύνθεση, η οποία μπορεί να χρησιμοποιείται σαν φάρμακο ή για την παρασκευή ενός φαρμάκου για την ανοσοθεραπεία όγκων ή για τον εμβολιασμό όγκων. Η εφεύρεση περιλαμβάνει επίσης μεθόδους για την παρασκευή φαρμάκων για την ανοσοθεραπεία όγκων ή για τον εμβολιασμό όγκων.
CY20061101216T 2000-07-28 2006-08-29 Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων CY1105179T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00116362 2000-07-28
EP01958002A EP1305041B1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren
PCT/EP2001/008455 WO2002009745A1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren

Publications (1)

Publication Number Publication Date
CY1105179T1 true CY1105179T1 (el) 2010-03-03

Family

ID=8169380

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101216T CY1105179T1 (el) 2000-07-28 2006-08-29 Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων

Country Status (20)

Country Link
US (2) US20030129206A1 (el)
EP (1) EP1305041B1 (el)
JP (1) JP2004505058A (el)
AT (1) ATE330626T1 (el)
AU (1) AU2001279775A1 (el)
BG (1) BG107482A (el)
CA (1) CA2417374A1 (el)
CY (1) CY1105179T1 (el)
CZ (1) CZ299669B6 (el)
DE (1) DE50110274D1 (el)
DK (1) DK1305041T3 (el)
ES (1) ES2267800T3 (el)
HK (1) HK1055562A1 (el)
HU (1) HUP0300772A3 (el)
NO (1) NO20030420L (el)
PL (1) PL358675A1 (el)
PT (1) PT1305041E (el)
SI (1) SI1305041T1 (el)
SK (1) SK822003A3 (el)
WO (1) WO2002009745A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
RU2324493C2 (ru) * 2003-02-20 2008-05-20 Юниверсити Оф Коннектикут Хелт Сентер Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP1974742A1 (en) * 2007-03-29 2008-10-01 LipoNova AG A method for improving the manufacturing process of a tumour vaccine
AU2010268367B2 (en) 2009-07-02 2016-10-20 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer
CN105807053B (zh) 2016-04-15 2019-04-02 苏州药明康德新药开发股份有限公司 一种肿瘤解离试剂在流式细胞检测中的应用
ES2908885T3 (es) 2017-07-05 2022-05-04 Vcc Medical Deutschland Gmbh Método para fabricar una vacuna tumoral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
DE19812004A1 (de) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung
WO1999047687A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
DE69939821D1 (de) * 1998-04-02 2008-12-11 Univ California Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature

Also Published As

Publication number Publication date
NO20030420D0 (no) 2003-01-27
BG107482A (bg) 2003-11-28
AU2001279775A1 (en) 2002-02-13
PL358675A1 (en) 2004-08-09
CZ299669B6 (cs) 2008-10-08
CZ2003179A3 (cs) 2004-01-14
PT1305041E (pt) 2006-09-29
HUP0300772A3 (en) 2005-11-28
HK1055562A1 (en) 2004-01-16
SK822003A3 (en) 2004-05-04
CA2417374A1 (en) 2003-01-27
US20070134275A1 (en) 2007-06-14
NO20030420L (no) 2003-01-27
EP1305041A1 (de) 2003-05-02
DE50110274D1 (de) 2006-08-03
JP2004505058A (ja) 2004-02-19
WO2002009745A1 (de) 2002-02-07
US20030129206A1 (en) 2003-07-10
DK1305041T3 (da) 2006-10-23
ES2267800T3 (es) 2007-03-16
HUP0300772A2 (en) 2003-08-28
ATE330626T1 (de) 2006-07-15
EP1305041B1 (de) 2006-06-21
SI1305041T1 (sl) 2006-12-31

Similar Documents

Publication Publication Date Title
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
IL145731A0 (en) A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
SE0002320D0 (sv) Malignant tumors
SI1255537T1 (sl) Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
HUP0204216A2 (en) A new use of antibodies as vaccines
DK0522078T3 (da) GP75 som en tumorvaccine mod melanom
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
EA200701071A1 (ru) Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором и их использование в лечении рака
MY141122A (en) Vaccine composition containing transforming growth factor alpha (tgf[alpha]). it use in malignant diseases therapy
MD3236985T3 (ro) Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor tipuri de cancere
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
MX2024002187A (es) Anticuerpos y conjugados de nectina-4.
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
WO2001048205A3 (en) Murine neu sequences and methods of use therefor
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
CY1111320T1 (el) Cripto ειδικα αντισωματα